Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 3, 2003, Pages 974-980

  Plotkin, Batya ^a   Kaidanovich, Oksana ^a   Talior, Ilana ^a   Eldar Finkelman, Hagit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE DERIVATIVE; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; L803; N MYRISTOYLGLYCYLLYSYLGLUTAMYLALANYLPROLYLPROLYLALANYLPROLYLPROLYLGLUTAMINYLSERYLP ROLINE; PEPTIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SPECIFICITY; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HORMONE ACTION; INSULIN LIKE ACTIVITY; INSULIN RESISTANCE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADIPOCYTES; ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIETARY FATS; DISEASE MODELS, ANIMAL; GLUCOSE TOLERANCE TEST; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INSULIN; MICE; MICE, INBRED C57BL; MOLECULAR MIMICRY; PEPTIDES; PHOSPHORYLATION;

EID: 0038811796     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.047381     Document Type: Article

References (43)

1. Cheng K, Creacy S, and Larner J (1983) 'Insulin-like' effects of lithium ion on isolated rat adipocytes. II. Specific activation of glycogen synthase. Mol Cell Biochem 56:183-189.
2. Cline GW, Johnson K, Regittnig W, Perret P, Tozzo E, Xiano L, Damico C, and Shulman GI (2002) Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes 51:2903-2910.
3. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L, et al. (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7:793-803.
4. Cohen P (1986) Muscle Glycogen Synthase, The Enzymes (Boyer P and Krebs EG eds), Academic Press, Orlando, FL.
5. Covic L, Misra M, Badar J, Singh C, and Kuliopulos A (2002) Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 10:1161-1165.
6. Cross DA, Alessi DR, Vandenheede JR, McDowell HE, Hundal HS, and Cohen P (1994) The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor-1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biochem J 303:21-26.
7. Damsbo P, Vaag A, Hother-Nielsen O, and Beck-Nielsen H (1991) Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34:239-245.
8. Davies SP, Reddy H, Caivano M, and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105.
9. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, and Damico LA (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277:35035-35043.
10. Eldar-Finkelman H, Agrast GM, Foord O, Fischer EH, and Krebs EG (1996) Expression and Characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity. Proc Natl Acad Sci USA 93:10228-10233.
11. Eldar-Finkelman H and Krebs EG (1997) Phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 impairs insulin action. Proc Natl Acad Sci 94:9660-9664.
12. Eldar-Finkelman H, Schreyer SA, Shinohara MM, LeBoeuf RC, and Krebs EG (1999) Increased glycogen synthase kinase-3 activity in diabetes and obesity prone C57BL/6J mice. Diabetes 48:1662-1666.
13. Emote M, Langille SE, and Czech MP (2001) A role for kinesin in insulin-stimulated GLUT4 glucose transporter translocation in 3T3-L1 adipocytes. J Biol Chem 276:10677-10682.
14. Fiol CJ, Mahrenholz AM, Wang Y, Roeske RW, and Roach PJ (1987) Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J Biol Chem 262:14042-14048.
15. Gould C and Wong CF (2002) designing specific protein kinase inhibitors: insights from computer simulations and comparative sequence/structure analysis. Pharmacol Ther 93:1690178.
16. Hawiger J (1999) Noninvasive intracellular delivery of functional peptides and proteins. Curr Opin Chem Biol 3:89-94.
17. Heinemann L, Pfutzner A, and Heise T (2001) Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary delivery. Curr Pharm Des 14:1327-1351.
18. Katagiri H, Asano T, Ishihara H, Inukai K, Shibasaki Y, Kikuchi M, Yazaki Y, and Oka Y (1996) Overexpression of catalytic subunit p110α of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1 adipocytes. J Biol Chem 271:16987-16990.
19. Lawrence JC, Guinovart JJ, and Larner J (1977) Activation of rat adipocyte glycogen synthase by insulin. J Biol Chem 252:444-450.
20. Lindsay MA (2002) Peptide-mediated cell delivery: application in protein target validation. Curr Opin Pharmacol 2:587-594.
21. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, Hasselager E, Larsen UD, Ribel U, Schaffer L, Vad K, et al. (1996) Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39:281-288.
22. Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, and Kahn CR (2002) Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Investig 109:141-149.
23. Morfini G, Szebenyi G, Elluru R, Ratner N, and Brady ST (2002) Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J 21:281-293.
24. Nikoulina SE, Ciaraldi-TP, Abrams-Carte L, Mudaliar S, Park KS, and Henry RR (1997) Regulation of glycogen synthase activity in cultured skeletal muscle cells from subjects with type II diabetes: role of chronic hyperinsulinemia and hyperglycemia. Diabetes 46:1017-1024.
25. Nikoulina SE, Ciaraldi TP, Mudaliar S, Carter L, Johnson K, and Henry RR (2002) Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 51:2190-2198.
26. Nikoulina SE, Ciaraldi TP, Mudailar S, Mohideen P, Carter L, and Henry RR (2000) Potential role of GSK-3 in skeletal muscle insulin resistance type 2 diabetes. Diabetes 49:263-271.
27. Ricort JM, Tanti JF, Van Obberghen E, and Le Marchand-Brustel Y (1996) Different effects of insulin and platelet-derived growth factor on phosphatidylinositol 3-kinase at the subcellular level in 3T3-L1 adipocytes. A possible explanation for their specific effects on glucose transport. Eur J Biochem 239:17-22.
28. Rowald M (1988) Clinical Pharmacokinetics: Concepts and Applications, 2nd ed, Lea & Febiger, Philadelphia.
29. Sarno S, Moro S, Meggio F, Zagotto G, Dal Ben D, Ghisellini P, Battistutta R, Zanotti G, and Pinna LA (2002) Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol Ther 93:159-168.
30. Schwarze SR, Ho A, Vocero-Akbani A, and Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science (Wash DC) 285:1569-1572.
31. Senel S, Kremer M, Nagy K, and Squier C (2001) Delivery of bioactive peptides and proteins across oral (buccal) mucosa. Curr Pharm Biotechnol 2:175-186.
32. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, and Shulman RG (1990) Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 22:223-228.
33. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, and Feinglos MN (1988) Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:1163-1167.
34. 14C-glucose. Anal Biochem 25:486-499.
35. Tung C-H and Weissleder R (2003) Arginine containing peptides as delivery vectors. Adv Drug Deliv Rev 55:281-994.
36. Ueki K, Yballe CM, Brachmann SM, Vicent D, Watt JM, Kahn CR, and Cantley LC (2002) Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 99:419-424.
37. Wang Y and Roach PJ (1993) Inactivation of rabbit muscle glycogen synthase by glycogen synthase kinase-3. Dominant role of the phosphorylation of Ser-640 (site-3a). J Biol Chem 268:23876-23880.
38. Wang J, Wu d and Shen W-C (2002) Structure-activity relationship of reversible lipidized peptides: studies of fatty acid-desmopression conjugates. Pharm Res 19:609-614.
39. Welsh GI and Proud CG (1993) Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J 294:625-629.
40. Williams D and Mitchell T (2002) Latest development in crystallography and structure-based design pf protein kinase inhibitors as drug candidates. Curr Opin Pharmacol 2:567.
41. Woodgett JR (2001) Judging a protein more than its name: GSK-3. Sci STKE 100:RE12.
42. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature (Lond) 415:389-395.
43. Zhang W, Depaoli-Roach AA, and Roach PJ (1993) Mechanisms of multisite phosphorylation and inactivation of rabbit muscle glycogen synthase. Arch Biochem Biophys 304:219-225.